Skip to main content
Premium Trial:

Request an Annual Quote

Scienion, Axela Ink Joint Array Development Agreement

NEW YORK (GenomeWeb) – German sample preparation firm Scienion and Canadian molecular diagnostics firm Axela today announced they have signed a joint marketing and development agreement to create and sell production systems and services for diagnostic and research products.

"This will provide commercialization partners with an integrated and scalable offering to address emerging diagnostic markets," including oncology, allergy, infectious disease, and other markets, the firms said in a statement.

Axela sells a variety of flow-through array technologies. "Our printing requirements are unique," Axela President Paul Smith said. "A precise and versatile liquid handling technology was necessary to meet these demanding requirements, while still providing our partners with a robust, go-to market production solution."

Financial and other details of the agreement were not disclosed.

Over the past year, Scienion has partnered with several firms including Grenier Bio-One, Axxin, Anteo, and QuantuMDx to incorporate its liquid handling and other sample prep technologies into various diagnostic tests and platforms.

Recently, Axela launched a collaboration with Pathology Associates Medical Laboratories to create multiplex assays to detect patient immunity to diseases that can be prevented with vaccines.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.